- Home
- NATR vs GOSS Comparison
NATR vs GOSS Comparison
Compare NATR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATR
- GOSS
- Stock Information
- Founded
- NATR 1972
- GOSS 2015
- Country
- NATR United States
- GOSS United States
- Employees
- NATR N/A
- GOSS N/A
- Industry
- NATR Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NATR Health Care
- GOSS Health Care
- Exchange
- NATR Nasdaq
- GOSS Nasdaq
- Market Cap
- NATR 254.1M
- GOSS 246.6M
- IPO Year
- NATR N/A
- GOSS 2019
- Fundamental
- Price
- NATR $13.06
- GOSS $1.01
- Analyst Decision
- NATR Strong Buy
- GOSS Strong Buy
- Analyst Count
- NATR 2
- GOSS 5
- Target Price
- NATR $19.50
- GOSS $9.20
- AVG Volume (30 Days)
- NATR 35.4K
- GOSS 878.6K
- Earning Date
- NATR 11-05-2024
- GOSS 11-07-2024
- Dividend Yield
- NATR N/A
- GOSS N/A
- EPS Growth
- NATR 191.23
- GOSS N/A
- EPS
- NATR 0.79
- GOSS N/A
- Revenue
- NATR $441,682,000.00
- GOSS $95,842,000.00
- Revenue This Year
- NATR $0.59
- GOSS N/A
- Revenue Next Year
- NATR $4.12
- GOSS N/A
- P/E Ratio
- NATR $16.61
- GOSS N/A
- Revenue Growth
- NATR 2.14
- GOSS N/A
- 52 Week Low
- NATR $10.81
- GOSS $0.45
- 52 Week High
- NATR $21.72
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- NATR 42.17
- GOSS 56.76
- Support Level
- NATR $13.15
- GOSS $0.96
- Resistance Level
- NATR $14.18
- GOSS $1.07
- Average True Range (ATR)
- NATR 0.43
- GOSS 0.07
- MACD
- NATR -0.02
- GOSS 0.01
- Stochastic Oscillator
- NATR 3.10
- GOSS 58.16
About NATR Nature's Sunshine Products Inc.
Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.